Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research.
|Telephone:||0870 166 6234|
|Address:||Hillcrest, Dodgeford Lane, Belton, Loughborough|
. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Phanes Therapeutics as a strategic partner to advance their oncology drug discovery pipeline.
16 March 2018Read in full
The 4th Annual Crown Bioscience Cambridge symposium this year focuses on immuno-oncology and future advances in cancer treatment. Don’t miss out on the chance to hear from AstraZeneca, Janssen, Merus, Kymab, Cantargia, Oxford BioMedica, Crescendo Biologics, and CrownBio, as well as networking with your peers.
15 February 2018Read in full